Skip to main content
. Author manuscript; available in PMC: 2022 May 11.
Published in final edited form as: Leuk Lymphoma. 2020 Aug 6;61(13):3188–3197. doi: 10.1080/10428194.2020.1795159

Figure 4.

Figure 4.

Prevalence of any grade TEAEs over time in the ibrutinib arm for (A) TEAEs of clinical interest and (B) TEAEs occurring in ≥30% of patients in the final analysis. aMajor hemorrhage TEAEs included serious/grade ≥3 hemorrhage and any grade central nervous system hemorrhage.